Targeted interception of signaling reactive oxygen species in the vascular endothelium

Therapeutic Delivery

Volumn 3, Issue 2, 2012, Pages 263-276

  Han, Jingyan ^a   Shuvaev, Vladimir V ^a   Muzykantov, Vladimir R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

hydrogen peroxide when activated by agonists including cytokines; Membrane enzyme complexes that produce superoxide and, in some cases; one of the major sources of signaling reactive oxygen species

Indexed keywords

CATALASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTENSION; INFLAMMATION; MOLECULAR PATHOLOGY; NANOENCAPSULATION; NONHUMAN; OXIDATIVE STRESS; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 84857175282     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.151     Document Type: Review

References (148)

1. Forman HJ, Maiorino M, Ursini F. Signaling functions of reactive oxygen species. Biochemistry 49(5), 835-842 (2010).
2. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction. molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10(10), 1713-1765 (2008).
3. Ichimura H, Parthasarathi K, Quadri S, Issekutz AC, Bhattacharya J. Mechano-oxidative coupling by mitochondria induces proinflammatory responses in lung venular capillaries. J. Clin. Invest. 111(5), 691-699 (2003). (Pubitemid 36278587)
4. Zimmerman MC, Dunlay RP, Lazartigues E et al. Requirement for Rac1-dependent NADPH oxidase in the cardiovascular and dipsogenic actions of angiotensin II in the brain. Circ. Res. 95(5), 532-539 (2004). (Pubitemid 39180933)
5. McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv. Myocardiol. 5, 183-189 (1985).
6. Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol. Chem. 387(12), 1521-1533 (2006). (Pubitemid 44837576)
7. Reddy PH. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular. Med. 10(4), 291-315 (2008).
8. Muzykantov VR. Targeting of superoxide dismutase and catalase to vascular endothelium. J. Control Release 71(1), 1-21 (2001). (Pubitemid 32195437)
9. Christofidou-Solomidou M, Muzykantov VR. Antioxidant strategies in respiratory medicine. Treat Respir. Med. 5(1), 47-78 (2006). (Pubitemid 43116813)
10. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol. Biol. 33(4), 319-327 (2005). (Pubitemid 41416281)
11. van der Vliet A. NADPH oxidases in lung biology and pathology: host defense enzymes, and more. Free Radic. Biol. Med. 44(6), 938-955 (2008).
12. Gongora MC, Qin Z, Laude K et al. Role of extracellular superoxide dismutase in hypertension. Hypertension 48(3), 473-481 (2006). (Pubitemid 44253743)
13. Hawkins BJ, Madesh M, Kirkpatrick CJ, Fisher AB. Superoxide flux in endothelial cells via the chloride channel-3 mediates intracellular signaling. Mol. Biol. Cell 18(6), 2002-2012 (2007). (Pubitemid 46911353)
14. Oakley FD, Abbott D, Li Q, Engelhardt J. Signaling components of redox active endosomes: the redoxosomes. Antioxid. Redox Signal. 11(6), 1313-1333 (2009).
15. Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 11(6), 1289-1299 (2009).
16. Shuvaev VV, Han J, Yu KJ et al. PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J. 25(1), 348-357 (2011).
17. Finkel T. Signal transduction by reactive oxygen species. J. Cell. Biol. 194(1), 7-15 (2011).
18. Finkel T. Signal transduction by mitochondrial oxidants. J. Biol. Chem. doi:10.1074/jbc.R111.271999 (2011) (Epub ahead of print).
19. Murphy MP, Holmgren A, Larsson NG et al. Unraveling the biological roles of reactive oxygen species. Cell. Metab. 13(4), 361-366 (2011).
20. Harrison DG, Gongora MC, Guzik TJ, Widder J. Oxidative stress and hypertension. J. Am. Soc. Hypertens. 1(1), 30-44 (2007). (Pubitemid 46696606)
21. Sedeek M, Hebert RL, Kennedy CR, Burns KD, Touyz RM. Molecular mechanisms of hypertension: role of NOX family NADPH oxidases. Curr. Opin Nephrol. Hypertens. 18(2), 122-127 (2009).
22. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97(8), 1916-1923 (1996).
23. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 34(1), 5-14 (2011).
24. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Diez J. Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol. Dial. Transplant. 16(Suppl. 1), 2-5 (2001). (Pubitemid 32492496)
25. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109(14), 1795-1801 (2004). (Pubitemid 38500684)
26. Landmesser U, Cai H, Dikalov S et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40(4), 511-515 (2002).
27. Jackson SP, Mistry N, Yuan Y. Platelets and the injured vessel wall: 'rolling into action': focus on glycoprotein Ib/V/IX and the platelet cytoskeleton. Trends Cardiovasc. Med. 10(5), 192-197 (2000). (Pubitemid 32229887)
28. Yao SK, McNatt J, Cui K et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation 88(6), 2888-2893 (1993). (Pubitemid 23360216)
29. Peire MA, Puig-Parellada P. Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. Pharmacol. Res. 38(5), 353-356 (1998). (Pubitemid 28515506)
30. Kuwano K, Ikeda H, Oda T et al. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis. Am. J. Physiol. 270(6 Pt 2), H1993-1999 (1996).
31. Krotz F, Sohn HY, Gloe T et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100(3), 917-924 (2002). (Pubitemid 34832618)
32. Salvemini D, de Nucci G, Sneddon JM, Vane JR. Superoxide anions enhance platelet adhesion and aggregation. Br. J. Pharmacol. 97(4), 1145-1150 (1989). (Pubitemid 20051928)
33. Ferroni P, Basili S, Falco A, Davi G. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid. Redox Signal. 6(4), 747-756 (2004). (Pubitemid 38890792)
34. Redondo PC, Salido GM, Rosado JA, Pariente JA. Effect of hydrogen peroxide on Ca2+ mobilisation in human platelets through sulphydryl oxidation dependent and independent mechanisms. Biochem. Pharmacol. 67(3), 491-502 (2004). (Pubitemid 38232889)
35. Gregg D, de Carvalho DD, Kovacic H. Integrins and coagulation: a role for ROS/ redox signaling? Antioxid. Redox Signal. 6(4), 757-764 (2004).
36. Gkaliagkousi E, Ferro A. Nitric oxide signalling in the regulation of cardiovascular and platelet function. Front Biosci. 16, 1873-1897 (2011).
37. Coleman LG Jr, Polanowska-Grabowska RK, Marcinkiewicz M, Gear AR. LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22). Blood 104(2), 380-389 (2004). (Pubitemid 38900018)
38. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb. Haemost. 105(Suppl. 1), S34-S42 (2011).
39. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of b 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107(3), 569-573 (1997). (Pubitemid 27102148)
40. Lopez D, Garcia-Valladares I, Palafox- Sanchez CA et al. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies to oxLig-1/beta-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am. J. Clin. Pathol. 121(3), 426-436 (2004). (Pubitemid 38298177)
41. Bouma B, de Groot PG, van den Elsen JM et al. Adhesion mechanism of human b(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18(19), 5166-5174 (1999). (Pubitemid 29465567)
42. Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/b2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 15(7), 478-483 (2006). (Pubitemid 44147097)
43. Ishikawa M, Stokes KY, Zhang JH, Nanda A, Granger DN. Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin. Circ. Res. 94(2), 239-244 (2004). (Pubitemid 38197457)
44. Simon F, Stutzin A. Protein kinase C-mediated phosphorylation of p47 phox modulates platelet-derived growth factor-induced H2O2 generation and cell proliferation in human umbilical vein endothelial cells. Endothelium 15(4), 175-188 (2008).
45. Sturrock A, Cahill B, Norman K et al. Transforming growth factor-beta1 induces NOX4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 290(4), L661-L673 (2006). (Pubitemid 43725071)
46. Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J. Lab. Clin. Med. 123(6), 874-881 (1994). (Pubitemid 2103605)
47. Herkert O, Djordjevic T, BelAiba RS, Gorlach A. Insights into the redox control of blood coagulation: role of vascular NADPH oxidase-derived reactive oxygen species in the thrombogenic cycle. Antioxid. Redox Signal. 6(4), 765-776 (2004).
48. Sanguigni V, Ferro D, Pignatelli P et al. CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J. Am. Coll. Cardiol. 45(1), 35-42 (2005). (Pubitemid 40052023)
49. Couzin-Frankel J. Inflammation bares a dark side. Science 330(6011), 1621 (2010).
50. Lonkar P, Dedon PC. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. Int. J. Cancer 128(9), 1999-2009 (2011).
51. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-l-cysteine. Proc. Natl Acad. Sci. USA 87(12), 4884-4888 (1990).
52. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science 312(5782), 1882-1883 (2006). (Pubitemid 43993698)
53. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kB signaling. Cell Res. 21(1), 103-115 (2011).
54. Reynaert NL, van der Vliet A, Guala AS et al. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc. Natl Acad. Sci. USA 103(35), 13086-13091 (2006). (Pubitemid 44338920)
55. Boueiz A, Hassoun PM. Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc. Res. 77(1), 26-34 (2009).
56. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem. Pharmacol. 77(12), 1763-1772 (2009).
57. Barnard ML, Matalon S. Mechanisms of extracellular reactive oxygen species injury to the pulmonary microvasculature. J. Appl. Physiol. 72(5), 1724-1729 (1992).
58. Han J, Shuvaev VV, Muzykantov VR. Catalase and superoxide dismutase conjugated with platelet-endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability caused by exogenous reactive oxygen species and vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 338(1), 82-91 (2011).
59. Alom-Ruiz SP, Anilkumar N, Shah AM. Reactive oxygen species and endothelial activation. Antioxid. Redox Signal. 10(6), 1089-1100 (2008). (Pubitemid 351451713)
60. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91(4), 1487-1500 (2001). (Pubitemid 32900340)
61. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol. 280(4), C719-C741 (2001).
62. Wojciak-Stothard B, Tsang LY, Paleolog E, Hall SM, Haworth SG. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 290(6), L1173-L1182 (2006). (Pubitemid 43830862)
63. Alexander JS, Alexander BC, Eppihimer LA et al. Inflammatory mediators induce sequestration of VE-cadherin in cultured human endothelial cells. Inflammation 24(2), 99-113 (2000). (Pubitemid 30127816)
64. Kevil CG, Oshima T, Alexander B, Coe LL, Alexander JS. H2O2-mediated permeability: role of MAPK and occludin. Am. J. Physiol. Cell Physiol. 279(1), C21-C30 (2000). (Pubitemid 30616618)
65. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J. Neurochem. 101(2), 566-576 (2007). (Pubitemid 46525283)
66. McCord JM, Edeas MA. SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed. Pharmacother. 59(4), 139-142 (2005). (Pubitemid 40603324)
67. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 11(11-12), 524-533 (2006).
68. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. NY Acad. Sci. 1201, 96-103 (2010).
69. Moens AL, Kass DA. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J. Cardiovasc. Pharmacol. 50(3), 238-246 (2007). (Pubitemid 47428970)
70. Van Assche T, Huygelen V, Crabtree MJ. Targeting vascular redox biology through antioxidant gene delivery: a historical view and current perspectives. Recent Pat. Cardiovasc. Drug Discov. 6(2), 89-102 (2011).
71. Muro S, Gajewski C, Koval M, Muzykantov VR. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 105(2), 650-658 (2005). (Pubitemid 40070749)
72. Muro S, Mateescu M, Gajewski C, Robinson M, Muzykantov VR, Koval M. Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am. J. Physiol. Lung Cell Mol. Physiol. 290(5), L809-L817 (2006). (Pubitemid 43725041)
73. Dziubla TD, Karim A, Muzykantov VR. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control Release 102(2), 427-439 (2005). (Pubitemid 40093764)
74. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into nonpolymeric magnetic nanoparticles. J. Control Release 146(1), 144-151 (2010).
75. Simone EA, Dziubla TD, Arguiri E et al. Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm. Res. 26(1), 250-260 (2009).
76. Simone EA, Dziubla TD, Discher DE, Muzykantov VR. Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules 10(6), 1324-1330 (2009).
77. Dziubla TD, Shuvaev VV, Hong NK et al. Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 29(2), 215-227 (2008). (Pubitemid 350017841)
78. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 33(6), 857-863 (2002). (Pubitemid 35232320)
79. Boissinot M, Kuhn LA, Lee P et al. Rational design and expression of a heparin-targeted human superoxide dismutase. Biochem. Biophys. Res. Commun. 190(1), 250-256 (1993). (Pubitemid 23227315)
80. Hernandez-Saavedra D, Zhou H, McCord JM. Anti-inflammatory properties of a chimeric recombinant superoxide dismutase: SOD2/3. Biomed. Pharmacother. 59(4), 204-208 (2005). (Pubitemid 40603334)
81. Watanabe N, Iwamoto T, Bowen KD, Dickinson DA, Torres M, Forman HJ. Bio-effectiveness of Tat-catalase conjugate: a potential tool for the identification of H2O2-dependent cellular signal transduction pathways. Biochem. Biophys. Res. Commun. 303(1), 287-293 (2003). (Pubitemid 36338238)
82. Nagata K, Iwasaki Y, Yamada T et al. Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. Respir. Med. 101(4), 800-807 (2007).
83. Epperly MW, Sikora CA, DeFilippi SJ et al. Pulmonary irradiation-induced expression of VCAM-I and ICAM-I is decreased by manganese superoxide dismutase-plasmid/ liposome (MnSOD-PL) gene therapy. Biol. Blood Marrow Transplant. 8(4), 175-187 (2002). (Pubitemid 34520532)
84. Supinski GS, Callahan LA. Polyethylene glycol-superoxide dismutase prevents endotoxin-induced cardiac dysfunction. Am. J. Respir. Crit. Care Med. 173(11), 1240-1247 (2006). (Pubitemid 43848395)
85. Joralemon MJ, McRae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem. Commun. 46(9), 1377-1393 (2010).
86. Wen J, Jiang X, Dai Y et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J. Sex. Med. 7(9), 3011-3022 (2009).
87. Payne RW, Murphy BM, Manning MC. Product development issues for PEGylated proteins. Pharm. Dev. Technol. 16(5), 423-440 (2011).
88. White CW, Jackson JH, Abuchowski A et al. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J. Appl. Physiol. 66(2), 584-590 (1989). (Pubitemid 19072904)
89. Yi X, Zimmerman MC, Yang R, Tong J, Vinogradov S, Kabanov AV. Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. Free Radic. Biol. Med. 49(4), 548-558 (2010).
90. Lee S, Yang SC, Heffernan MJ, Taylor WR, Murthy N. Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug. Chem. 18(1), 4-7 (2007). (Pubitemid 46145988)
91. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 23(5), 1384-1395 (2009).
92. Rosenbaugh EG, Roat JW, Gao L et al. The attenuation of central angiotensin II-dependent pressor response and intraneuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials 31(19), 5218-5226 (2010).
93. Klyachko NL, Manickam DS, Brynskikh AM et al. Cross-linked antioxidant nanozymes for improved delivery to CNS. Nanomedicine doi:10.1016/j.nano.2011.05. 010 (2011) (Epub ahead of print).
94. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr. Med. Chem. 15(2), 172-177 (2008). (Pubitemid 351234620)
95. Lin SJ, Shyue SK, Shih MC et al. Superoxide dismutase and catalase inhibit oxidized low-density lipoprotein-induced human aortic smooth muscle cell proliferation: role of cell-cycle regulation, mitogen-activated protein kinases, and transcription factors. Atherosclerosis 190(1), 124-134 (2007).
96. Epperly MW, Guo HL, Jefferson M et al. Cell phenotype specific kinetics of expression of intratracheally injected manganese superoxide dismutase-plasmid/liposomes (MnSOD-PL) during lung radioprotective gene therapy. Gene Ther. 10(2), 163-171 (2003). (Pubitemid 36582588)
97. Danel C, Erzurum SC, Prayssac P et al. Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury. Hum. Gene Ther. 9(10), 1487-1496 (1998). (Pubitemid 28379088)
98. Folz RJ, Abushamaa AM, Suliman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J. Clin. Invest. 103(7), 1055-1066 (1999). (Pubitemid 29169614)
99. Segal BH, Han W, Bushey JJ et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One 5(3), e9631 (2010).
100. Finigan JH. The coagulation system and pulmonary endothelial function in acute lung injury. Microvasc. Res. 77(1), 35-38 (2009).
101. Varani J, Ward PA. Mechanisms of endothelial cell injury in acute inflammation. Shock 2(5), 311-319 (1994).
102. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13(3), 789-794 (2007). (Pubitemid 46340350)
103. Doerschuk CM, Quinlan WM, Doyle NA et al. The role of P-selectin and ICAM-1 in acute lung injury as determined using blocking antibodies and mutant mice. J. Immunol. 157(10), 4609-4614 (1996). (Pubitemid 126449383)
104. Esmon CT. The interactions between inflammation and coagulation. Br. J. Haematol. 131(4), 417-430 (2005). (Pubitemid 43899639)
105. Yao H, Yang SR, Kode A et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem. Soc. Trans. 35(Pt 5), 1151-1155 (2007). (Pubitemid 350206448)
106. Oakley FD, Abbott D, Li Q, Engelhardt JF. Signaling components of redox active endosomes: the redoxosomes. Antioxid. Redox Signal. 11(6), 1313-1333 (2009).
107. Kim DW, Kim SY, Lee SH et al. Protein transduction of an antioxidant enzyme: subcellular localization of superoxide dismutase fusion protein in cells. BMB Rep. 41(2), 170-175 (2008).
108. Muzykantov VR. Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin. Drug Deliv. 2(5), 909-926 (2005). (Pubitemid 41488849)
109. McIntosh DP, Tan XY, Oh P, Schnitzer JE. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl Acad. Sci. USA 99(4), 1996-2001 (2002). (Pubitemid 34169003)
110. Pasqualini R, McDonald DM, Arap W. Vascular targeting and antigen presentation. Nat. Immunol. 2(7), 567-568 (2001).
111. Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. 339(7), 472-474 (1998). (Pubitemid 28377692)
112. Simone E, Ding BS, Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res. 335(1), 283-300 (2009).
113. Stan RV, Kubitza M, Palade GE. PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc. Natl Acad. Sci. USA 96(23), 13203-13207 (1999).
114. Wilson A, Zhou W, Champion HC et al. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol. Ther. 12(3), 510-518 (2005). (Pubitemid 41150137)
115. Shuvaev VV, Muzykantov VR. Targeted modulation of reactive oxygen species in the vascular endothelium. J. Control Release 153(1), 56-63 (2011).
116. Danilov SM, Gavrilyuk VD, Franke FE et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am. J. Physiol. Lung Cell Mol. Physiol. 280(6), L1335-L1347 (2001).
117. Oh P, Li Y, Yu J et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429(6992), 629-635 (2004). (Pubitemid 38812308)
118. Pasqualini R, Koivunen E, Kain R et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60(3), 722-727 (2000). (Pubitemid 30094573)
119. Harari OA, Wickham TJ, Stocker CJ et al. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther. 6(5), 801-807 (1999). (Pubitemid 29243653)
120. Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 104(17), 2107-2112 (2001). (Pubitemid 33027054)
121. Shuvaev VV, Tliba S, Pick J et al. Modulation of endothelial targeting by size of antibody- antioxidant enzyme conjugates. J. Control Release 149(3), 236-241 (2011).
122. Muzykantov VR, Atochina EN, Ischiropoulos H, Danilov SM, Fisher AB. Immunotargeting of antioxidant enzyme to the pulmonary endothelium. Proc. Natl Acad. Sci. USA 93(11), 5213-5218 (1996). (Pubitemid 26159428)
123. Atochina EN, Balyasnikova IV, Danilov SM, Granger DN, Fisher AB, Muzykantov VR. Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am. J. Physiol. 275(4 Pt 1), L806-L817 (1998).
124. Scherpereel A, Wiewrodt R, Christofidou- Solomidou M et al. Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB J. 15(2), 416-426 (2001). (Pubitemid 32141433)
125. Kozower BD, Christofidou-Solomidou M, Sweitzer TD et al. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol. 21(4), 392-398 (2003). (Pubitemid 36397659)
126. Shuvaev VV, Christofidou-Solomidou M, Bhora F et al. Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J. Pharmacol. Exp. Ther. 331(2), 404-411 (2009).
127. Muzykantov VR, Atochina EN, Kuo A et al. Endothelial cells internalize monoclonal antibody to angiotensin-converting enzyme. Am. J. Physiol. 270(5 Pt 1), L704-L713 (1996).
128. Nowak K, Hanusch C, Nicksch K et al. Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting- enzyme antibodies. Eur. J. Cardiothorac. Surg. 37(4), 859-863 (2010).
129. Nowak K, Weih S, Metzger R et al. Immunotargeting of catalase to lung endothelium via anti-angiotensin-converting enzyme antibodies attenuates ischemia-reperfusion injury of the lung in vivo. Am. J. Physiol. Lung Cell Mol. Physiol. 293(1), L162-L169 (2007). (Pubitemid 47080724)
130. Preissler G, Loehe F, Huff IV et al. Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation 92(4), 380-387 (2011).
131. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci 24(9), 471-478 (2003). (Pubitemid 37088172)
132. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat. 82(1-4), 119-127 (2007).
133. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem. 278(25), 22546-22554 (2003). (Pubitemid 36830310)
134. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc. Natl Acad. Sci. USA 88(22), 10045-10048 (1991). (Pubitemid 21915772)
135. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32(1), 59-64 (1998). (Pubitemid 28324125)
136. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95(3), 588-593 (1997). (Pubitemid 27063033)
137. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc. Res. 68(1), 26-36 (2005). (Pubitemid 41253553)
138. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61(4), 290-302 (2009).
139. McCord JM, Wong K, Stokes SH, Petrone WF, English D. Superoxide and inflammation: a mechanism for the anti-inflammatory activity of superoxide dismutase. Acta Physiol. Scand. Suppl. 492, 25-30 (1980).
140. Valdivia A, Perez Y, Dominguez A et al. Improved anti-inflammatory and pharmacokinetic properties for superoxide dismutase by chemical glycosidation with carboxymethylchitin. MacroMol. Biosci. 5(2), 118-123 (2005). (Pubitemid 40803837)
141. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv. Drug Deliv. Rev. 54(4), 587-606 (2002). (Pubitemid 34615549)
142. Matsui T, Yamagishi S, Nakamura K, Inoue H. Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. J. Int. Med. Res. 35(6), 886-891 (2007). (Pubitemid 350238421)
143. Mitsopoulos P, Omri A, Alipour M, Vermeulen N, Smith MG, Suntres ZE. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int. J. Pharm. 363(1-2), 106-111 (2008).
144. Bonder CS, Knight D, Hernandez-Saavedra D, McCord JM, Kubes P. Chimeric SOD2/3 inhibits at the endothelial-neutrophil interface to limit vascular dysfunction in ischemia-reperfusion. Am. J. Physiol. Gastrointest. Liver Physiol. 287(3), G676-G684 (2004). (Pubitemid 39096635)
145. Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR. Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either. extracellular or intracellular superoxide. J. Pharmacol. Exp. Ther. 323(2), 450-457 (2007). (Pubitemid 350005112)
146. Muro S, Wiewrodt R, Thomas A et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116(Pt 8), 1599-1609 (2003). (Pubitemid 36527505)
147. Horgan MJ, Lum H, Malik AB. Pulmonary edema after pulmonary artery occlusion and reperfusion. Am. Rev. Respir. Dis. 140(5), 1421-1428 (1989). (Pubitemid 19276234)
148. Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid. Redox Signal. 11(7), 1651-1667 (2009).